$CBIO potential to make a large move 🔥$CBIO looks like it has potential to make a large move soon, Also it's #4 in list of top Fintel Gamma Squeeze list📈
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−45.72 USD
−37.88 M USD
0.00 USD
About GlycoMimetics Inc.
Operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers
CBIO CBIO = my return will focus only on a few stocks to keep .. minimum 5 days max 1 month ... MARKETS SHOW PANIC IS THE PERFECT TIME TO INVEST IN CONTRARIAN PHARMACEUTICAL ... This company has También noté in the super column green an incremental increase de volumen, que puede haber sido verificado .
CBIO - FALLING WEDGE PLAY - 15-30% HERE - 30M FLOAT - NO DEBTAll,
I think CBIO is a good play down here maybe wait and see for the break, but overall should be an easy pop. Also end of 2021 or before first dosed patient results. Combination would be deadly at least a 30%er if positive. Low enough float to play with TA alone though.
TightIf it stays tight around the $6.0-6.8 range until March we will see a break either up or down and I possibly will ride the wave.
$CBIO Cup and Handle?this one has amazing potential for the long term
had a nice run with this one last week for 50% profits. kept a small core position that i will be adding to for long
i61.CBIOBeta-R:Journal. Risk Management: Compound .Level : PA . Time: Short-term - Intermediate . This is just my view follow if it aligns with yours. Ideas are not repeated rather updated.Worry about risk only.
CBIO - DAILY CHART Hi, today we are going to talk about Catalyst Biosciences and its current landscape.
Catalyst Biosciences is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company has been soaring over the announcement that the compa
$CBIO MAY BE SLOWLY GETTING READY TO ATTACK "GAP" TERRITORYUptick in volume and relatively clean sky above 200 SMA
VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia.Dr. Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg,
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of CBIO is 13.27 USD — it has decreased by −15.99% in the past 24 hours. Watch Crescent Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Crescent Biopharma, Inc. stocks are traded under the ticker CBIO.
CBIO stock has risen by 2.24 K% compared to the previous week, the month change is a 2.24 K% rise, over the last year Crescent Biopharma, Inc. has showed a 2.24 K% increase.
CBIO stock is 23.53% volatile and has beta coefficient of 0.88. Track Crescent Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Crescent Biopharma, Inc. there?
Yes, you can track Crescent Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Crescent Biopharma, Inc. is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
CBIO earnings for the last quarter are −5.00 USD per share, whereas the estimation was −5.00 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are 0.00 USD per share. See more details about Crescent Biopharma, Inc. earnings.
Crescent Biopharma, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CBIO net income for the last quarter is −2.34 M USD, while the quarter before that showed −7.22 M USD of net income which accounts for 67.55% change. Track more Crescent Biopharma, Inc. financial stats to get the full picture.
No, CBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 17, 2025, the company has 26 employees. See our rating of the largest employees — is Crescent Biopharma, Inc. on this list?
Like other stocks, CBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Crescent Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Crescent Biopharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Crescent Biopharma, Inc. stock shows the buy signal. See more of Crescent Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.